Articles On Vectus Biosystems (ASX:VBS)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX200 closed +0.5% higher on Tuesday on the back of a big lift in the Mining sector.  Lithium stocks led, with IGO (ASX:IGO) and Pilbara (ASX:PLS) gaining around 3%.  Iron ore miners  rallied after the Nymex CFR China, 62% Fe price swu...

The ASX 200 traded sideways on Tuesday, closing the day flattish as gains in healthcare stocks were offset by losses in other sectors. Source: Market Index  Healthcare gained after the Albanese government approved an increase in private hea...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

The ASX 200 had another fine day, ending with a 0.73% gain overall Sectors wise, Tech and Real Estate were the winners, while Materials dipped as a whole, partly due to Rio and Fortescue  Standout small-cap performers: R3D, PAC, and the ju...

S&P/ASX 200 closes up 1% – its best performance in about a week  All sectors bar IT and Utilities had green days, with Discretionary and Utilities outperforming Resources & Energy Group had a +183% stonker of a day on its you-beaut...

For the first day of the trading week the market rallied, gaining one per cent. The boost came after the United States debt ceiling bill was signed into law, avoiding a catastrophic default. Asian markets were also up. In the green...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Aussie markets expended a lot of energy to go precisely nowhere Guatam Adani left with less than US$93 billion after Hindenburg got into his shorts I had a really lovely holiday, and it’s great to be back at work. No, really…   It’s been...

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Little joy for investors in December with traditional Christmas rally not eventuating in 2022 Meteoric Resources leads December winners after positive metallurgical results at its new Caldeira project. Symbio Holdings saw its share price p...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

Drug discovery and development company Vectus Biosystems (ASX: VBS) has launched a $4.5 million capital raising to accelerate a phase 1b clinical trial of lead candidate VB0004 to treat fibrosis and hypertension. The raising will be conduct...

ASX 200 ends 0.7% higher Small cap index flat NYM, BEZ, CPH best in show    Lithium keeps finding another gear. The analysts at Citi lifted target forecasts after the Marrickville government and others besides prepare to throw some suppor...

Welcome to the end of the start of the week. We trust you’ve all had a restful weekend, full of whatever it is you like to do when you’re not reading about stocks and stuff, and completely devoid of stuff you hate, like housework, your exte...

Fibrotic diseases specialist Vectus Biosystems (ASX: VBS) has confirmed that it will move to the next phase of testing of its lead drug for treating fibrosis and hypertension. In its September quarter report, the company says phase 1a clini...

Emerging gold miner Tietto Minerals has a new Chinese Mining giant as a substantial shareholder Environment play LGI has new substantial shareholders since listing on the ASX last week Lunnon Metals loses substantial shareholders while Bas...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc...

ASX 200 jumps on blue cap strength Small caps skulk around parity New Hope Coal: So. Much. New. Hope.   The benchmark is killing Tuesday, it’s up about 1.3% on big performances from the banks and the miners. The small cap XEC index is fla...

Biotechnology company Vectus Biosystems (ASX: VBS) has announced the completion of its phase 1a study of lead drug candidate VB0004 to treat fibrosis and hypertension. It had been the company’s first in-human trial to evaluate the safety, t...

Biotron commences human trial of COVID-19 Pancreatic trial news from Noxopharm and Clarity Pharma Vectus completes dosing of last cohort   Biotron (ASX:BIT) jumped 6% this morning after announcing the start of a human trial of its lead an...

Ahead of enticing pharmaceutical partners, Vectus Biosystems (ASX: VBS) is confident that positive results will continue to flow from the ongoing phase one trial of its lead drug VB0004 which treats fibrosis and high blood pressure. The bio...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

Benchmark down 1.6%, small caps 2% Shares dive on surprise size of rate hike  Dateline Resources lifts on 100m intercept   In some miserable pre-rate day trade the small caps index and the ASX200 were down 1.5% and 1% respectively as trad...

Vectus announced promising Phase 1 study results Emyria’s CBD capsule demonstrates  bioavailability and dose safety profile Bod Australia also reports promising results on its cannabis extract study   Vectus up 13% on Phase 1 results Fibr...

The S&P/ASX 200 Health Care Index (ASX: XHJ) is in the red today, but one ASX biotech share is beating the trend. The Vectus Biosystems Ltd (ASX: VBS) share price is soaring 13.6%, currently trading at $1.25. In contrast, the ASX 200...

Peter Switzer talks with Vectus Biosystems (VBS) CEO, Maurie Stang.

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

It’s been an emotional ride for fans of the ASX200 (XJO) which, alongside the Emerging Companies (XEC) index, (down 0.6%) gave up its early gains in a topsy-turvy Monday session. Just after the close, the XJO was weepingly flat – well, up 0...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Trading Places is Stockhead’s semi-regular, pretty damn fascinating recap of the latest red flag buying and selling of ASX small cap shares.  It is here that the rubber really hits the road for fund managers, stakeholders, distant (and not-...

At the time of writing, the ASX 200 Health Index (XHJ) is down by 1.90%, while the benchmark ASX 200 has fallen by 0.3%. Genomics specialist Genetic Technologies (ASX:GTG) says that its laboratory in Fitzroy, Melbourne has received simultan...

Wall Street down ahead of long weekend Queen Elizabeth has reportedly tested positive for COVID-19, but doctors say she is in good spirits with only minor symptoms. To the markets, and the standoff between Russia and Ukraine continues to ca...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...